Get the Stockscreener App
13.93
1.62%
-0.23
After Hours:
13.93
Day One Biopharmaceuticals Inc stock is traded at $13.93, with a volume of 1.46M.
It is down -1.62% in the last 24 hours and up +0.65% over the past month.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
See More
Previous Close:
$14.16
Open:
$14.09
24h Volume:
1.46M
Relative Volume:
1.52
Market Cap:
$1.39B
Revenue:
-
Net Income/Loss:
$-167.48M
P/E Ratio:
-6.0565
EPS:
-2.3
Net Cash Flow:
$-197.47M
1W Performance:
-2.31%
1M Performance:
+0.65%
6M Performance:
-15.68%
1Y Performance:
+13.53%
1-Day Range:
$13.65
$14.46
1-Week Range:
$13.65
$14.61
52-Week Range:
$9.67
$18.07
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
Name
Day One Biopharmaceuticals Inc
Sector
Industry
Phone
650 484-0899
Address
2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-25-23 | Downgrade | BofA Securities | Buy → Underperform |
| Feb-08-23 | Initiated | CapitalOne | Overweight |
| Feb-03-23 | Initiated | Oppenheimer | Perform |
| Dec-15-22 | Initiated | H.C. Wainwright | Buy |
| Dec-14-22 | Initiated | Needham | Buy |
| Dec-05-22 | Initiated | Goldman | Buy |
| Dec-01-22 | Initiated | BofA Securities | Buy |
View All
Day One Biopharmaceuticals Inc Stock (DAWN) Latest News
Taking on analysts’ expectations and winning: Day One Biopharmaceuticals Inc (DAWN) - SETE News
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Sees Large Growth in Short Interest - MarketBeat
An Analysis of Day One Biopharmaceuticals Inc (DAWN)’s Potential Price Growth - Knox Daily
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Sold by Maverick Capital Ltd. - MarketBeat
Holdings of Day One Biopharmaceuticals Inc (DAWN) are aligned with the stars - SETE News
Deerfield Management Company L.P. Series C Acquires 1,157,825 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Investor’s Toolkit: Key Ratios for Assessing Day One Biopharmaceuticals Inc (DAWN)’s Performance - The Dwinnex
Day One Biopharmaceuticals Inc (DAWN)’s stock price range in the last year - US Post News
Dayforce (NYSE:DAY) Upgraded by KeyCorp to “Strong-Buy” - Defense World
Equities Analysts Issue Forecasts for Dayforce Inc's Q3 2024 Earnings (NYSE:DAY) - MarketBeat
Dayforce (NYSE:DAY) Stock Rating Upgraded by KeyCorp - MarketBeat
Insider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Sells 40,831 Shares of Stock - Defense World
Logos Global Management LP Sells 1,465,000 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dayforce Inc (DAY) receives an Overweight rating from Piper Sandler - Knox Daily
Capital One Financial Corp. [COF] Insider Activity: An Update for Investors - Knox Daily
Dayforce started with bullish views at KeyBanc on growth potential of software platform - Seeking Alpha
Ally Bridge Group NY LLC Buys Shares of 536,095 Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
Taking a Closer Look At 1stdibs.com Inc (DIBS) Following Its Recent Trade - Knox Daily
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Down 4.8% - MarketBeat
Avoro Capital Advisors LLC Acquires New Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Victory Capital Management Inc. Takes Position in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Hollencrest Capital Management Buys Shares of 88,949 Dayforce Inc (NYSE:DAY) - Defense World
Day One Biopharmaceuticals Inc [DAWN] HEAD OF R&D makes an insider sale of 30,000 shares worth 426,675. - Knox Daily
Darden Restaurants, FedEx And 3 Stocks To Watch Heading Into Thursday - Benzinga
How the (DAWN) price action is used to our Advantage - Stock Traders Daily
Is Day One Biopharmaceuticals Inc (DAWN) a good investment opportunity? - US Post News
BofA Securities Upgrades Day One Biopharmaceuticals Inc (DAWN) to a Buy from an Underperform - Knox Daily
Analytical Lens: Exploring Day One Biopharmaceuticals Inc (DAWN)’s Financial Story Through Ratios - The Dwinnex
Check out these key findings about Day One Biopharmaceuticals Inc (DAWN) - SETE News
Analysts Set Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Target Price at $35.71 - MarketBeat
How should investors view Day One Biopharmaceuticals Inc (DAWN)? - US Post News
Day One Biopharmaceuticals Inc [DAWN] Records 50-Day SMA of $14.33 - Knox Daily
Day One Biopharmaceuticals Inc (DAWN) Stock: A Year of Market Fluctuations - The InvestChronicle
Day one biopharmaceuticals executive sells $426k in stock - Investing.com
Insider Selling: Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells 30,000 Shares of Stock - MarketBeat
Investing in Day One Biopharmaceuticals Inc (DAWN) Is Getting More Attractive - Knox Daily
Investors in cash trouble should check out Day One Biopharmaceuticals Inc (DAWN) - SETE News
Day One Biopharmaceuticals Inc (DAWN) Stock: A Year of Declines and Increases - The InvestChronicle
Is Day One Biopharmaceuticals Inc (DAWN) worth investing in despite its overvalued state? - US Post News
Day One Biopharmaceuticals Inc’s latest rating changes from various analysts - Knox Daily
It makes sense and dollars to buy Day One Biopharmaceuticals Inc (DAWN) stock - SETE News
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Short Interest Update - MarketBeat
DAWN’s 2023 Market Dance: Down -6.37% – Time to Invest? - The InvestChronicle
Day One Biopharmaceuticals Inc (DAWN)’s Market Momentum: Closing Strong at 14.08, Down -2.36 - The Dwinnex
Day One Biopharmaceuticals Inc (DAWN) stock analysis: A simple moving average approach - US Post News
Prepare Yourself for Liftoff: Day One Biopharmaceuticals Inc (DAWN) - SETE News
Day One Biopharmaceuticals Inc (DAWN) gets rating Upgrade from BofA Securities - Knox Daily
Day One Biopharmaceuticals Inc [DAWN] Shares Jump Approximately 2.23% Over the Year - Knox Daily
Day one biopharmaceuticals executive sells over $36k in stock By Investing.com - Investing.com Australia
Day one Biopharmaceuticals general counsel sells shares worth over $44k - Investing.com Australia
Market Recap Check: Day One Biopharmaceuticals Inc (DAWN)’s Positive Finish at 14.09, Up/Down 1.22 - The Dwinnex
Day One Biopharmaceuticals Inc Stock (DAWN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):